Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point for two distinct therapeutic pathways: Hodgkin’s lymphoma (HL) and ...

The epidemiology of tumor lysis syndrome is evolving with the introduction of newer therapies. The occurrence of tumor lysis syndrome has become a less predictable but increasingly important aspect of ...